Table 3.
Summary of discontinuation rate due to AEs and inefficacy at different time points among the included studies (12 comparative studies evidence).
| Registry | Study name | Intervention | N | Discontinuation rate due to AEs (%) | Discontinuation rate due to inefficacy (%) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6 m | 12 m | 18 m | 24 m | 36 m | 6 m | 12 m | 18 m | 24 m | 36 m | ||||
| Biologic-naive | |||||||||||||
| DREAM | Flendrie et al. 2003 [1] | ADA | 94 | — | 11.0 | — | — | — | — | 11.0 | — | — | — |
| ETN | 14 | — | 7.0 | — | — | — | — | 7.0 | — | — | — | ||
| INF | 83 | — | 24.0 | — | — | — | — | 10.0 | — | — | — | ||
| LOHREN | Marchesoni et al. 2009 [8] | ADA | 303 | — | — | — | — | 19.8 | — | — | — | — | 14.9 |
| ETN | 242 | — | — | — | — | 11.6 | — | — | — | — | 12.8 | ||
| INF | 519 | — | — | — | — | 20.4 | — | — | — | — | 20.0 | ||
|
| |||||||||||||
| Mixed (biologic pretreated and biologic-naive) | |||||||||||||
| SCQM | Pan et al. 2009 [13] | ADA | 882 | 4.7 | 7.7 | 10.7 | 12.4 | 16.2 | — | — | — | — | — |
| ETN | 887 | 2.8 | 7.4 | 12.5 | 15.4 | 21.1 | — | — | — | — | — | ||
| INF | 595 | 4.7 | 10.0 | 14.8 | 20.3 | 24.7 | — | — | — | — | — | ||
| RABBIT | Strangfeld et al. 2009 [14] | ADA + LEF | 174 | 12.0 | 21.6 | 26.0 | 27.3 | — | 13.1 | 23.8 | 28.0 | 31.2 | — |
| ADA + MTX | 566 | 12.8 | 18.8 | 23.8 | 25.0 | — | 12.8 | 18.5 | 22.4 | 24.6 | 32.4 | ||
| ETN + LEF | 144 | 8.5 | 15.7 | 19.3 | 22.1 | — | 9.6 | 19.9 | 22.6 | 30.6 | |||
| ETN + MTX | 448 | 9.9 | 13.5 | 16.3 | 18.7 | 20.6 | 10.4 | 17.1 | 20.5 | 24.5 | 30.0 | ||
| INF + LEF | 76 | 17.8 | 27.8 | — | — | — | 16.1 | 25 | 37.4 | 43.5 | — | ||
| INF + MTX | 361 | 17.3 | 22.6 | 27.8 | 30.5 | 37.1 | 12.8 | 23.3 | 28.3 | 32.2 | — | ||
| ADA | 8.3 (1622) N = 2 |
13.1 (1622) N = 2 |
16.9 (1622) N = 2 |
18.4 (1622) N = 2 |
16.2 (882) N = 1 |
— | — | — | — | — | |||
| Pooled discontinuation rate | ETN | 5.5 (1479) N = 2 |
10.1 (1479) N = 2 |
14.3 (1479) N = 2 |
17.1 (1479) N = 2 |
20.9 (1335) N = 2 |
— | — | — | — | — | ||
| INF | 10.1 (1032) N = 2 |
15.8 (1032) N = 2 |
19.7 (956) N = 2 |
24.2 (956) N = 2 |
29.4 (956) N = 2 |
— | — | — | — | — | |||
|
| |||||||||||||
| Overall comparative evidence | |||||||||||||
| ADA | 8.3 (1622) N = 2 |
13.0 (1716) N = 3 |
16.9 (1622) N = 2 |
18.4 (1622) N = 2 |
17.3 (1185) N = 2 |
12.8 (740) N = 1 |
18.7 (834) N = 2 |
23.8 (740) N = 1 |
26.2 (740) N = 1 |
26.4 (869) N = 2 |
|||
| Pooled discontinuation rate | ETN | 5.5 (1479) N = 2 |
10.1 (1493) N = 3 |
14.3 (1479) N = 2 |
17.1 (1479) N = 2 |
19.5 (1577) N = 3 |
10.1 (592) N = 1 |
17.5 (606) N = 2 |
20.9 (592) N = 1 |
26.0 (592) N = 1 |
23.9 (690) N = 2 |
||
| INF | 10.1 (1032) N = 2 |
16.4 (1115) N = 3 |
19.7 (956) N = 2 |
24.2 (956) N = 2 |
26.2 (1475) N = 3 |
13.3 (437) N = 1 |
21.3 (520) N = 2 |
29.7 (437) N = 1 |
34.1 (437) N = 1 |
20.0 (519) N = 1 |
|||
ADA: adalimumab; DREAM: Dutch Rheumatoid Arthritis Monitoring; ETN: etanercept; INF: infliximab; LEF: leflunomide; LOHREN: Lombardy Rheumatology Network; M: Months; MTX: methotrexate; RABBIT: rheumatoid arthritis observation of biologic therapy; SCQM: Swiss Clinical Quality Management in Rheumatic Diseases.